As the market stabilizes after the pandemic peaks, 2024 marks a crucial year for regulatory compliance. The focus shifts from quantity to absolute quality, with a stringent focus on performance requirements, biocompatibility, and the new draft revisions of the standard (prEN 14683).
In this in-depth article, we’ll explore what’s changing in 2024, the technical details of the laboratory tests required for certification, and how CIMAC supports companies in ensuring compliance with the Medical Device Regulation (MDR) 2017/745.
The Regulatory Context 2024: Where Are We Today?
Medical face masks, commonly known as “surgical” masks, are classified as Medical Devices (MD). Unlike PPE (Personal Protective Equipment such as FFP2 masks), their primary purpose is to protect the patient from infectious agents released by healthcare workers, although in some configurations they also protect the wearer.
In 2024, the harmonized reference remains the EN 14683:2019+AC:2019 version. However, this year sees progress in work on the revision of the standard (often referred to as prEN 14683 or draft 2024).
Why an update?
The regulatory update and revision underway in 2024 respond to several needs:
01) Alignment with MDR (EU) 2017/745: The European Medical Devices Regulation imposes much more stringent general safety and performance requirements (GSPR) than the previous directive. The technical standard must reflect this rigor.
02) Sustainability: The environmental impact of disposable masks is beginning to be discussed, introducing concepts that could influence future material requirements.
03) Clarity in testing methods: The update aims to reduce ambiguity in the interpretation of laboratory tests, ensuring that a result obtained in Italy is perfectly comparable to one obtained in Germany or France.
For manufacturers, “Update 2024” means not only looking at the technical standard, but ensuring that the entire technical file fully meets the post-market surveillance and risk management criteria imposed by Europe today.
Classification of Masks: Types and Differences
The EN 14683 standard classifies masks into three main categories, based solely on laboratory test results. Understanding these differences is essential for correctly positioning the product on the market.
Type I: The entry-level mask for patients
Type I masks must guarantee a bacterial filtration efficiency (BFE) of ≥ 95%. They are primarily intended for use by patients and others to reduce the risk of spreading infections, particularly in epidemic or pandemic situations. They are not intended for use by healthcare workers in operating rooms.
Type II: The Medical Standard
Type II masks require a BFE ≥ 98%. They are the standard devices for medical use, suitable for clinical procedures where there is no risk of splashing bodily fluids.
Type IIR: Superior Protection
The “R” stands for Resistance. Type IIR masks combine the high filtration of Type II (BFE ≥ 98%) with splash resistance. They are specifically designed for operating rooms and other medical environments where the risk of exposure to blood or other bodily fluids is significant.
Draft News and Future Prospects
While the tests listed above are the current “gold standard,” the industry is closely monitoring the discussions of the CEN/TC 205 technical committee regarding future revisions. Here’s what could change or become more stringent in the near future:
Strengthening Breathability Requirements
There is a push to improve operator comfort. Future revisions may require even lower Delta P values for the same filtration performance, forcing manufacturers to seek higher-quality, more technologically advanced nonwoven and meltblown fabrics.
Sustainability and the “Green Deal”
Even the medical sector is not immune to the ecological transition. While safety always takes precedence over sustainability in the medical field, discussions are beginning to address requirements for the biodegradability or recycling of uncontaminated materials. CIMAC is at the forefront of monitoring these developments to advise manufacturers on the materials of the future.
Labeling and Traceability (UDI)
The 2024 update places significant emphasis on labeling. Simply writing “Surgical Mask” is no longer sufficient. Packaging must clearly display: (a) The reference to the EN 14683 standard and the type (e.g., Type IIR). (b) The unique device identifier (UDI), which is mandatory for traceability according to the MDR. (c) Clear warnings if the product contains latex or other allergens.
Labeling and Traceability (UDI)
Why trust CIMAC for EN 14683 testing? In today’s market, a test report isn’t just a piece of paper; it’s your company’s export passport and legal protection.
- Accreditation and Recognition The tests performed must be issued by competent laboratories. CIMAC’s reputation ensures that the results are accepted by the relevant authorities and hospitals at the tender stage.
- Specialist Technical Support We don’t just provide a number (Pass/Fail). Our technicians assist customers in interpreting the data. If a mask fails the Splash Resistance test, we analyze the layer structure (spunbond/meltblown) together to determine how to improve the product.
- Speed and Reliability Time to market is essential. Our streamlined procedures reduce waiting times for microbiological and physical test results, without compromising scientific rigor.
Conclusions: Preparing for the Future
Compliance with EN 14683 by 2024 is not a point of arrival, but a dynamic process. With the tightening of post-market controls resulting from MDR 2017/745 and future revisions to the technical standard on the horizon, medical device manufacturers must remain vigilant regarding the quality of materials and manufacturing processes.
Investing in accurate and certified laboratory tests isn’t an expense, but an investment in patient safety and brand strength. If you need to certify a new line of masks or renew your periodic surveillance tests, contact the CIMAC team today. We’re ready to guide you through the requirements of EN 14683 and ensure your device is ready for the challenges of the modern healthcare market.